MARAVAI LIFESCIENCES HOLDINGS INC (MRVI)
Health Care · Life science reagents and contract manufacturing · NASDAQ
Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large biotech and pharmaceutical customers.
What MARAVAI LIFESCIENCES HOLDINGS INC does
Maravai LifeSciences provides life science reagents, custom synthesis services, and manufacturing capabilities for the research, development, and commercial production of vaccines and therapeutics. The company operates through TriLink (custom nucleotides and oligonucleotides), Cygnus (life science reagents), and CleanCap (a capping technology for mRNA vaccines and therapies). Its products enable pharmaceutical and biotechnology customers to manufacture mRNA-based vaccines and other advanced therapeutic modalities.
Themes: ["mRNA vaccines","synthetic biology","life science manufacturing","vaccine production","therapeutic manufacturing"]
Fundamentals
- Price$5.97 as of 2026-07-09 close
- Market cap$1.5B as of 2026-07-10
- 1-year return+116.3% as of 2026-07-09 close
- Net margin-51.1% as of 2026-07-10
- Gross margin+29.3% as of 2026-07-10
- ROE-44.7% as of 2026-07-10
- Debt / equity1.28 as of 2026-07-10
- Revenue growth (YoY)-15.3% as of 2026-07-10
- Revenue CAGR (3y)-40.5% SEC XBRL
- Beta0.58 as of 2026-07-10
Key risks (from latest filing)
["High dependency on a limited number of customers for mRNA vaccine programs; revenue from CleanCap is subject to factors outside management control including vaccine program adoption rates and regulatory approvals","Operating results are prone to significant fluctuation due to volatility in customer spending and vaccine development cycles; recent organizational restructuring and workforce reductions create execution risk","Customer use of products in novel mRNA vaccine and therapy modalities exposes the company to regulatory risk, negative clinical outcomes, and potential obsolescence if alternative therapies are developed or regulatory scrutiny increases"]
Competitors & peers
- Chemgenes Corporation
- ChemRNA
- Cytiva (Cytiva Life Sciences)
- Lonza
- Evonik
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.